The inter-link of ageing, cancer and immunity: findings from real-world retrospective study

作者：Xiaomin Fu, Peng Qin, Fanghui Li, Huifang Zhu, Hongqin You, Yong Zhang, Benling Xu, Tiepeng Li, Fang Zhang, Lu Han, Lingdi Zhao, Baozhen Ma, Zibing Wang, Quanli Gao · 发表于：Immunity & Ageing · 年份：2023 · DOI：10.1186/s12979-023-00399-9 · 被引用次数：16 · 研究领域：Cancer Immunotherapy and Biomarkers、Multiple and Secondary Primary Cancers、Immune cells in cancer

Abstract Background Although the concept of declined immune function associated with cancer has been accepted extensively, real-world clinical studies focusing on analysis of the peripheral blood immune changes underlying ageing, immunity and cancer are scarce. Methods In this case-control study, we retrospectively analysed 1375 cancer patients and enrolled 275 age and gender matched healthy individuals. Flow cytometry was conducted to assess the immune changes. Further analysis was examined by SPSS 17.0 and GraphPad Prism 9 software. Results Cancer patients showed obviously decreased CD3 + T, CD3 + CD4 + Th, CD3 + CD8 + CTL, CD19 + B, CD16 + CD56 + NK cell counts and lower percentage of PD-1 (programmed cell death protein-1, PD-1) positive cells than healthy control ( P < 0.0001). For cancer patients, the reference range of circulating percentage of PD-1 + CD45 + cells, PD-1 + CD3 + T cells, PD-1 + CD3 + CD4 + Th cells and PD-1 + CD3 + CD8 + CTL (Cytotoxic T Lymphocyte, CTL) were 11.2% (95% CI 10.8%-11.6%), 15.5% (95% CI 14.7%-16.0%), 15.4% (95% CI 14.9%-16.0%) and 14.5% (95% CI 14.0%-15.5%), respectively. Moreover, the reduction of CD3 + T, CD3 + CD4 + Th, CD3 + CD8 + CTL, CD19 + B cell counts accompanied with age and stage advancing ( P < 0.05). CD16 + CD56 + NK cells decreased with stage, but elevated in aged and male cancer patients ( P < 0.05). Additionally, the percentage of PD-1 positive cells varied across cancer types, raised with age and stage. Head and ne...